Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

MDCX

Medicus Pharma Ltd

Feb 06 • 04:00PM ET

1.11

+0.02 1.83 %

Healthcare • Drug Manufacturers - General • Canada • NASD

Held by: IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.11	Insider Own	33.30%	Shs Outstand	20.97M	Perf Week	-6.72%
Market Cap	28.36M	Forward P/E	-	EPS next Y	-0.78	Insider Trans	0.00%	Shs Float	7.88M	Perf Month	-29.30%
Enterprise Value	26.86M	PEG	-	EPS next Q	-0.15	Inst Own	18.03%	Short Float	11.28%	Perf Quarter	-51.74%
Income	-33.84M	P/S	-	EPS this Y	-67.88%	Inst Trans	-8.20%	Short Ratio	2.83	Perf Half Y	-49.08%
Sales	0.00M	P/B	-	EPS next Y	59.85%	ROA	-368.01%	Short Interest	0.89M	Perf YTD	-27.45%
Book/sh	-0.04	P/C	3.27	EPS next 5Y	9.77%	ROE	-2237.54%	52W High	8.94 -87.58%	Perf Year	-59.04%
Cash/sh	0.34	P/FCF	-	EPS past 3/5Y	-106.88% -	ROIC	-	52W Low	1.07 3.73%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.60% 9.91%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-66.23%	Oper. Margin	-	ATR (14)	0.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.92	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	27.70	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.92	EPS Q/Q	-261.32%	SMA20	-14.29%	Beta	-2.28	Target Price	19.67
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-29.85%	Rel Volume	1.61	Prev Close	1.09
Employees	12	LT Debt/Eq	-	Earnings	Nov 21	SMA200	-57.56%	Avg Volume	314.05K	Price	1.11
IPO	Jan 26, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-18.52% -	Trades		Volume	506,349	Change	1.83%

Jan-23-26 07:30AM	Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony (ACCESSWIRE)
Jan-22-26 07:30AM	Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix Long-Term Economic and Development Profile (GlobeNewswire)
Jan-20-26 07:30AM	Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026 (GlobeNewswire)
Jan-12-26 07:30AM	Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women (GlobeNewswire) -5.81%
Jan-05-26 07:30AM	Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates (GlobeNewswire)
07:30AM	Loading…
Dec-22-25 07:30AM	Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform (ACCESSWIRE) -7.69%
Dec-15-25 07:30AM	Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin (GlobeNewswire)
Dec-05-25 03:20PM	Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement (ACCESSWIRE) +6.77%
Dec-01-25 08:00AM	Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President (ACCESSWIRE) -10.23%
Nov-25-25 08:16AM	Maxim Group Reaffirms Buy on Medicus Pharma Ltd (MDCX) With $20 Target (Insider Monkey)
Nov-24-25 08:00AM	Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers (GlobeNewswire) -7.04%
Nov-17-25 07:30AM	Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin (ACCESSWIRE)
Nov-14-25 05:00PM	Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights (ACCESSWIRE)
Nov-13-25 07:30AM	Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin (ACCESSWIRE) -5.44%
Oct-29-25 07:30AM	Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome (ACCESSWIRE)
07:30AM	Loading…
07:30AM	Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT in Patients with Gorlin Syndrome (GlobeNewswire)
Oct-22-25 07:30AM	Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin (ACCESSWIRE)
Oct-14-25 08:07AM	The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets (ACCESSWIRE)
Oct-13-25 07:30AM	Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025 (ACCESSWIRE) -6.45%
Oct-07-25 07:30AM	Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE (ACCESSWIRE)
Sep-29-25 07:30AM	Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject (ACCESSWIRE)
Sep-24-25 09:26AM	Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX) (Newsfile) -8.93%
07:30AM	Medicus Pharma Ltd. To Present at Brookline Capital Markets (ACCESSWIRE)
Sep-18-25 07:30AM	Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing (ACCESSWIRE)
Sep-08-25 07:30AM	Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) (ACCESSWIRE) +11.17%
Sep-02-25 07:30AM	Medicus Pharma Ltd. Completes Acquisition of Antev Limited (Newsfile) +7.22%
Aug-21-25 07:30AM	Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights (Newsfile) +20.10%
Aug-04-25 07:30AM	Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines (Newsfile) -7.39%
Jul-23-25 07:30AM	Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders (Newsfile)
Jul-21-25 07:30AM	Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025 (Newsfile)
07:30AM	Loading…
Jul-08-25 07:30AM	Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA) (Newsfile) -12.06%
Jun-30-25 07:30AM	Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK (Newsfile)
Jun-23-25 07:30AM	Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer (Newsfile) -6.02%
Jun-12-25 07:30AM	Medicus Pharma Ltd. to Present at 2025 Bio International Convention (Newsfile)
Jun-09-25 07:30AM	Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses (Newsfile)
Jun-02-25 01:40PM	Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering (Newsfile)
May-30-25 07:00AM	Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari (GlobeNewswire) -29.85%
May-29-25 08:30PM	Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering (Newsfile) -11.77%
May-22-25 07:30AM	Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) (Newsfile) -8.17%
Apr-28-25 07:30AM	Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction (Newsfile)
Apr-21-25 07:30AM	Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) (Newsfile)
Mar-10-25 04:05PM	Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering (Newsfile) +11.48% -23.24%
Mar-06-25 08:30PM	Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering (Newsfile)
07:30AM	Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) (Newsfile)
Feb-27-25 07:30AM	Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) (GlobeNewswire) +12.16%
Feb-14-25 07:30AM	Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) (GlobeNewswire) +19.48%
Feb-11-25 07:41AM	Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV) (Newsfile)
Dec-12-24 07:30AM	Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch (GlobeNewswire)
Dec-02-24 07:30AM	Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region (GlobeNewswire) -8.72%
Nov-18-24 07:30AM	Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer (Newsfile) -6.70%
Nov-15-24 04:47PM	Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States (Newsfile) -15.47%

Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. It develops a product, SkinJectTM, with an indication for basal cell carcinoma. The company was founded on April 30, 2008 and is headquartered in Toronto, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Quinlan James P.	Chief Financial Officer	Aug 13 '25	Option Exercise	1.08	145,000	156,250	274,147	Aug 14 04:01 PM
VELOCITY FUND PARTNERS, LP	10% Owner	May 20 '25	Sale	7.72	75,000	578,940	3,248,741	May 21 12:57 PM
VELOCITY FUND PARTNERS, LP	Major Shareholders	May 20 '25	Proposed Sale	195.49	118,000	23,067,500		May 20 03:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MDCX

Medicus Pharma Ltd

Upgrade your FINVIZ experience